The Estée Lauder Companies has announced a minority investment in luxury clinical skincare brand 111SKIN.
Founded in 2012 by plastic and reconstructive surgeon Dr. Yannis Alexandrides, the brand was originally developed to support post-procedure healing and has since expanded into a portfolio of more than 30 products, including its Black Diamond and Reparative collections.
At the core of 111SKIN is its NAC Y2™ complex, designed to support skin repair. The brand operates within the growing clinical skincare segment, where treatment-led formulations and medical expertise are increasingly influencing consumer demand.
“Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results,” said Stéphane de La Faverie, President and CEO of The Estée Lauder Companies. “111SKIN exemplifies this shift, translating Dr. Alexandrides’ experience into high-performance luxury skin care.”
111SKIN is distributed through luxury retail, e-commerce and spa channels, including Harrods, Nordstrom, Bluemercury, Mandarin Oriental and Aman, with North America accounting for around 40% of sales in 2025.
“We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111SKIN,” said Dr. Yannis and Eva Alexandrides. “We look forward to building on our momentum and driving future growth together,” added CEO Vanessa Goddevrind.
Dr. Alexandrides will remain actively involved in the business following the investment.The move reflects continued industry interest in science-led, high-performance skincare.
